drugset

drugset / Trial / NCT02280434

Phase 1 Study Accessing the Safety and Tolerability of CBP-307

NCT02280434 ↗

Phase 1 Completed 64 enrolled Connect Biopharm LLC Nucleus Network Ltd · collab Tigermed Consulting Co., Ltd · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CBP-307 following oral single and multiple escalating dose administration in healthy subjects.

Timeline

Start: 2014-11
Primary completion: 2015-08
Completion: 2015-08

Publications

Lickliter J, Yang X, Guo J, Pan W, Wei Z. Icanbelimod (CBP-307), a next-generation Sphingosine-1-phosphate receptor modulator, in healthy men: pharmacokinetics, pharmacodynamics, safety, and tolerability in a randomized trial in Australia. Front Immunol. 2024 Jun 17;15:1380975. doi: 10.3389/fimmu.2024.1380975. eCollection 2024.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	CBP-307	Unknown	0.1 mg	Oral
Comparator	CBP-307	Unknown	0.15 mg	Oral
Comparator	CBP-307	Unknown	0.25 mg	Oral
Comparator	CBP-307	Unknown	0.5 mg	Oral
Comparator	CBP-307	Unknown	2.5 mg	Oral

Indications